Esmirtazapine

DB06678InvestigationalSmall molecule

Esmirtazapine, known by the standardized identifier SCH 900265, was under development by Organon to treat insomnia and vasomotor symptoms associated with menopause. Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses... This includes inverse agonist activity of H1 and 5-HT2 receptors and antagonism of α2-adrenergic receptors.

Mechanism: Pharmacologically active on Histamine H1 receptor, 5-hydroxytryptamine receptor 2A, and 5-hydroxytryptamine receptor 2C
Curator reviewed
Primary indication: Investigated for use/treatment in insomnia and sleep disorders.Curator reviewed
Formula / weight: C₁₇H₁₉N₃ · 265.36 g/mol (avg)
Code names: ORG-44-20 · ORG-50,081 · SCH 900265

Resolves to

Compound

UNII4685R51V7MCAS61337-87-9ChEMBLCHEMBL1366933PubChem3085218

Structure

InChIKeyRONZAEMNMFQXRA-MRXNPFEDSA-NSMILES[H][C@]12CN(C)CCN1C1=C(CC3=CC=CC=C23)C=CC=N1

Targets

P35367HRH1P28223HTR2AP28335HTR2C

What you can answer from here — as of September 13, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1,266Drug interactionsStructured to mechanism, not free text

7Clinical trialsPhase, status and sponsor resolved per trial

17+ReferencesStructured and connected to the statements they support

Which drugs share a target with Esmirtazapine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account